Heat sensitivity of human parvovirus B19

被引:44
|
作者
Yunoki, M
Tsujikawa, M
Urayama, T
Sasaki, Y
Morita, M
Tanaka, H
Hattori, S
Takechi, K
Ikuta, K
机构
[1] Osaka Univ, Microbial Dis Res Inst, Dept Virol, Suita, Osaka 5650871, Japan
[2] Mitsubishi Pharma Corp, Div Pharmaceut Res, Prot Res Lab, Osaka, Japan
关键词
bioassay; parvovirus B19; plasma products; viral safety; virus inactivation;
D O I
10.1046/j.1423-0410.2003.00280.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives To date there has been no published report on a systematic evaluation of the heat sensitivity of human parvovirus B19 (B19) and the related safety of the plasma-derived fractionated products. In this study, we examined the heat sensitivity of B19 by using the infectivity assay with cultured cells. Materials and Methods The heat sensitivity of B19 was examined by measuring the reduction in viral infectivity titres after heating liquid containing B19 at 60 degreesC. Viral infectivity was assayed by detection of viral antigens or viral mRNA in infected cells. As a control, canine parvovirus (CPV) was also heat-treated. Results B19 displayed quite different inactivation kinetics to CPV when both were heated in liquid at 60 degreesC. In sharp contrast to the latter, B19 was rapidly inactivated within 1 h when the virus was suspended in 5% or 25% human serum albumin solution, phosphate-buffered saline, or complete medium. However, B19 appeared to be resistant to heat inactivation in liquid containing 60% sucrose. Conclusions The heat sensitivity of B19 in liquid was clearly different from that of CPV. Significantly, the efficiency to inactivate B19 and reduce its infectivity following heating in liquid was mainly affected by the composition of the solutions used for virus suspension.
引用
收藏
页码:164 / 169
页数:6
相关论文
共 50 条
  • [41] 0 Human parvovirus B19: A review
    Rogo, L. D.
    Mokhtari-Azad, T.
    Kabir, M. H.
    Rezaei, F.
    ACTA VIROLOGICA, 2014, 58 (03) : 199 - 213
  • [42] HUMAN PARVOVIRUS B19 AND HYDROPS FETALIS
    ANDERSON, MJ
    KHOUSAM, MN
    MAXWELL, DJ
    GOULD, SJ
    HAPPERFIELD, LC
    SMITH, WJ
    LANCET, 1988, 1 (8584): : 535 - 535
  • [43] Persistence of human parvovirus B19 in human tissues
    Söderlund-Venermo, M
    Hokynar, K
    Nieminen, J
    Rautakorpi, H
    Hedman, K
    PATHOLOGIE BIOLOGIE, 2002, 50 (05): : 307 - 316
  • [44] Parvovirus B19 (PV-B19) and human diseases
    Yavorkovsky, LI
    TERAPEVTICHESKII ARKHIV, 1995, 67 (11) : 56 - 58
  • [45] Diagnosis and management of human parvovirus B19 infection
    Ramirez, MM
    Mastrobattista, JM
    CLINICS IN PERINATOLOGY, 2005, 32 (03) : 697 - +
  • [46] Human Parvovirus B19 in Solid Organ Transplantation
    Eid, A. J.
    Chen, S. F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 201 - 205
  • [47] Human parvovirus B19 infection in an immunocompromised host
    Pandey, Soumya
    CLINICAL CASE REPORTS, 2020, 8 (12): : 3609 - 3610
  • [48] The human parvovirus B19 and its interactions in vivo
    Morinet, F
    PATHOLOGIE BIOLOGIE, 2002, 50 (05): : 283 - 284
  • [49] RISKS ASSOCIATED WITH HUMAN PARVOVIRUS B19 INFECTION
    不详
    ARCHIVES OF DERMATOLOGY, 1989, 125 (04) : 475 - 480
  • [50] Human parvovirus B19 infection and antiphospholipid antibodies
    von Landenberg, Philipp
    Lehmann, Hartwig W.
    Modrow, Susanne
    AUTOIMMUNITY REVIEWS, 2007, 6 (05) : 278 - 285